
(Healthday News) — Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer’s drug whose high price tag and unproven benefits have prompted widespread controversy. Medicare’s announcement came the same day that leaders of two House committees that are investigating Aduhelm’s approval asked drugmaker Biogen… read on > read on >